GYEONGGI-DO, Korea & GERMANTOWN, Md.--(BUSINESS WIRE)--D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc. and Theraly Fibrosis Inc., today announced that it has completed a $137.1 million Series B round of financing from U.S. and Korean investors.
D&D raises $137M to fund inflammation tech out of JHU
Johns Hopkins scientists raise $137M megaround for a trio of spinouts looking to tackle Alzheimer’s, Parkinson’s and fibrosis
- Fierce Biotech
D&D bags $137M to fund midphase Alzheimers', Parkinson's trials